title: EUHASS: The European Haemophilia Safety Surveillance system.
abstract: Pharmacovigilance is an essential element of any drug treatment and considering the history of adverse events due to products used to treat inherited bleeding disorders, it should be an integral component of modern haemophilia treatment. Because inherited bleeding disorders and adverse events are rare, a multicentre, preferably multinational, adverse event reporting scheme for all clotting factor products is required. EUHASS is a European, prospective, multicentre adverse event reporting scheme in the field of inherited bleeding disorders.
authors.affiliation: University of Sheffield, UK. m.makris@sheffield.ac.uk
authors.forename: M
authors.initials: M
authors.lastname: Makris
authors.forename: G
authors.initials: G
authors.lastname: Calizzani
authors.forename: K
authors.initials: K
authors.lastname: Fischer
authors.forename: E A
authors.initials: EA
authors.lastname: Gilman
authors.forename: C R M
authors.initials: CR
authors.lastname: Hay
authors.forename: R
authors.initials: R
authors.lastname: Lassila
authors.forename: T
authors.initials: T
authors.lastname: Lambert
authors.forename: C A
authors.initials: CA
authors.lastname: Ludlam
authors.forename: P M
authors.initials: PM
authors.lastname: Mannucci
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems / Q000941:ethics / Q000458:organization & administration / Q000706:statistics & numerical data; D025861:Blood Coagulation Disorders, Inherited / Q000188:drug therapy; D001779:Blood Coagulation Factors / Q000009:adverse effects; D016208:Databases, Factual; D005060:Europe; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000009:adverse effects
chemical_list: D001779:Blood Coagulation Factors; D011994:Recombinant Proteins